FH wins GSK asthma account

The agency has been brought on board following a competitive pitch to handle comms support for Seretide, GSK's asthma and Chronic Obstructive Pulmonary Disease (COPD) treatment.

Seretide was launched in the UK in 1999 for asthma and was then licensed for use in COPD in 2003.

‘Asthma and COPD are both serious respiratory conditions affecting over nine million people in the UK,' said GSK COPD brand manager Stéphanie Meinsen-Antunes, COPD Brand Manager, GSK.

Asthma is one of the most common chronic diseases in the world, affecting approximately 300 million people worldwide. COPD takes the lives of around 22,000 people in the UK each year.

Fleishman-Hillard London healthcare director Cristina Benson will head up the account.